PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-142.73%
Negative net income growth while TRVN stands at 10.91%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
55.79%
Some D&A expansion while TRVN is negative at -0.97%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
71.34%
Lower deferred tax growth vs. TRVN's 6359.48%, implying fewer future tax liabilities. David Dodd would confirm there’s no short-term tax shock instead.
-22.08%
Negative yoy SBC while TRVN is 37.52%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
83.34%
Slight usage while TRVN is negative at -103.30%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
76.76%
AP growth well above TRVN's 100.00%. Michael Burry would be concerned about potential late payments or short-term liquidity strain relative to competitor.
-41.25%
Both reduce yoy usage, with TRVN at -102.39%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
-22.08%
Negative yoy while TRVN is 4.57%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
9.39%
Some CFO growth while TRVN is negative at -69.75%. John Neff would note a short-term liquidity lead over the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-3.94%
Both yoy lines negative, with TRVN at -1.60%. Martin Whitman suspects an environment prompting net new borrowings or weaker paydowns across the niche.
-35.14%
Negative yoy issuance while TRVN is 0.00%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.